Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic

This guidance provides recommendations to industry regarding postmarketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during an influenza pandemic.

Source: FDA Center for Drug Evaluation and Research - What's New - February 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news